MPH MD - Ardelyx Chief Officer
| ARDX Stock | USD 7.81 0.02 0.26% |
Executive
MPH MD is Chief Officer of Ardelyx
| Age | 60 |
| Address | 400 Fifth Avenue, Waltham, MA, United States, 02451 |
| Phone | 510 745 1700 |
| Web | https://www.ardelyx.com |
Ardelyx Management Efficiency
The company has return on total asset (ROA) of (0.1383) % which means that it has lost $0.1383 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4764) %, meaning that it created substantial loss on money invested by shareholders. Ardelyx's management efficiency ratios could be used to measure how well Ardelyx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.23 in 2024. Return On Capital Employed is likely to drop to -0.27 in 2024. At this time, Ardelyx's Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 47.1 M in 2024, whereas Total Assets are likely to drop slightly above 180.1 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael Howell | Zura Bio Limited | 47 | |
| Kenneth MD | Lexicon Pharmaceuticals | 67 | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Gayle Gironda | Inozyme PharmaInc | N/A | |
| Lisa DeFrancesco | Lexicon Pharmaceuticals | 44 | |
| Kristen Alexander | Lexicon Pharmaceuticals | 56 | |
| Matthew Beck | Hookipa Pharma | N/A | |
| Dixon Terry | Lexicon Pharmaceuticals | N/A | |
| Michael Szumera | Hookipa Pharma | N/A | |
| Desiree Gendron | Lexicon Pharmaceuticals | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Chas Schultz | Lexicon Pharmaceuticals | N/A | |
| Sanjay Zaveri | PDS Biotechnology Corp | N/A | |
| David Brady | Zura Bio Limited | N/A | |
| Roman Necina | Hookipa Pharma | 56 | |
| Lisa MD | Seres Therapeutics | 65 | |
| Daniel Courtney | Hookipa Pharma | N/A | |
| Gary Whale | Zura Bio Limited | 50 | |
| MD MSc | Verastem | 67 | |
| Daniel Trepanier | Hepion Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.14 |
Ardelyx Leadership Team
Elected by the shareholders, the Ardelyx's board of directors comprises two types of representatives: Ardelyx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ardelyx. The board's role is to monitor Ardelyx's management team and ensure that shareholders' interests are well served. Ardelyx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ardelyx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elizabeth Esq, Chief Secretary | ||
| Susan Rodriguez, Chief Officer | ||
| Michael Raab, CEO and President and Director | ||
| Elizabeth Grammer, Vice President General Counsel | ||
| CPA MST, CFO Treasurer | ||
| Robert Felsch, Senior Officer | ||
| Caitlin Lowie, Vice Relations | ||
| David Rosenbaum, Sr. VP of Drug Devel. | ||
| Kimia Keshtbod, Mang Relations | ||
| Robert Blanks, Chief Officer | ||
| Mike Kelliher, Executive Strategy | ||
| Karen Harrigan, Director Devel | ||
| Charon Sr, Chief Officer | ||
| Dan Pavicich, Director Devel | ||
| MPH MD, Chief Officer |
Ardelyx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ardelyx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | (0.54) % | ||||
| Current Valuation | 1.75 B | ||||
| Shares Outstanding | 233.98 M | ||||
| Shares Owned By Insiders | 1.68 % | ||||
| Shares Owned By Institutions | 61.19 % | ||||
| Number Of Shares Shorted | 35.17 M | ||||
| Price To Earning | (2.11) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ardelyx offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ardelyx's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ardelyx Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ardelyx Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ardelyx. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Ardelyx Stock please use our How to Invest in Ardelyx guide.Note that the Ardelyx information on this page should be used as a complementary analysis to other Ardelyx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Ardelyx Stock analysis
When running Ardelyx's price analysis, check to measure Ardelyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ardelyx is operating at the current time. Most of Ardelyx's value examination focuses on studying past and present price action to predict the probability of Ardelyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ardelyx's price. Additionally, you may evaluate how the addition of Ardelyx to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Ardelyx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ardelyx. If investors know Ardelyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ardelyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.28) | Revenue Per Share 0.705 | Quarterly Revenue Growth 3.048 | Return On Assets (0.14) | Return On Equity (0.48) |
The market value of Ardelyx is measured differently than its book value, which is the value of Ardelyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ardelyx's value that differs from its market value or its book value, called intrinsic value, which is Ardelyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ardelyx's market value can be influenced by many factors that don't directly affect Ardelyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ardelyx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ardelyx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ardelyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.